Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1000-1006

  Kavanaugh, Arthur ^a   Ritchlin, Christopher ^b   Rahman, Proton ^c   Puig, Lluis ^d   Gottlieb, Alice B ^e   Li, Shu ^f   Wang, Yuhua ^f   Noonan, Lenore ^f   Brodmerkel, Carrie ^f   Song, Michael ^f   Mendelsohn, Alan M ^f   McInnes, Iain B ^g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e TUFTS MEDICAL CENTER   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ARTHROPATHY; ARTICLE; BONE EROSION; DRUG DOSE COMPARISON; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HUMAN; JOINT CAVITY; JOINT DESTRUCTION; JOINT SPACE NARROWING; JOINT SWELLING; JOINT TENDERNESS; MULTICENTER STUDY (TOPIC); OSTEOLYSIS DEFORMITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; VAN DER HEIJDE SHARP SCORE;

ANTI-TNF; PSORIATIC ARTHRITIS; SPONDYLOARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CROSS-OVER STUDIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84899922972     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204741     Document Type: Article

References (24)

1. Day MS, Nam D, Goodman S, et al. Psoriatic arthritis. J Am Acad Orthop Surg 2012;20: 28-37.
2. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Investig 2011;41: 1361-6.
3. Maeda S, Hayami Y, Naniwa T, et al. The Th17/IL-23 axis and natural immunity in psoriatic arthritis. Int J Rheumatol 2012;2012:539683.
4. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo controlled trial (PHOENIX 1). Lancet 2008;371: 1665-74. (Pubitemid 351671883)
5. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo controlled trial (PHOENIX 2). Lancet 2008;371: 1675-84. (Pubitemid 351671884)
6. Griffiths CE, Strober BE, van de Kerkhof P, et al.; on behalf of the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362: 118-28.
7. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373: 633-40.
8. McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT I Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet 2013;382: 780-9.
9. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiologic and biologic anti-tumor-necrosis-factor therapy: 1-year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 2 trial. Ann Rheum Dis 2014. Published Online First: 30 Jan 2014. doi:10.1136/annrheumdis-2013-204655.
10. van der Heijde D, Landewé R, Klareskog L, et al. Presentation and analysis of data on radiographic outcome in clinical trials. Arthritis Rheum 2005;52: 49-60. (Pubitemid 40129232)
11. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35: 26-34.
12. Conover WJ. Practical Nonparametric Statistics. 2nd edn. New York: John Wiley & Sons, Inc., 1980: 318-20.
13. Bruynesteyn K, Boers M, Kostense P, et al. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64: 179-82. (Pubitemid 40193607)
14. Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 2013;14:101.
15. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17. (Pubitemid 40288513)
16. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111: 821-31. (Pubitemid 37074957)
17. Koshy PJ, Henderson N, Logan C, et al. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002;61: 704-13. (Pubitemid 34787708)
18. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18: 1069-76.
19. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56: 476-88.
20. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50: 2264-72. (Pubitemid 38924405)
21. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56: 2698-707. (Pubitemid 47237288)
22. Kavanaugh A, van der Heijde D, McInnes IM, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Ann Rheum Dis 2012;64: 2504-17.
23. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007;56: 3575-82. (Pubitemid 350100690)
24. Baker JF, George M, Baker DG, et al. Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis. Rheumatology 2011;50: 2100-7.